Home
About
Overview
Sharing Data
ORCID
Help
History (2)
CHARACTERIZATION OF ENHANCER IN RIBOSOMAL DNA
Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade.
See All 2 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade.
Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Pract. 2019 Apr; 25(3):551-557.
View in:
PubMed
subject areas
Adrenal Cortex Hormones
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
Female
Humans
Lung Neoplasms
Male
Middle Aged
Programmed Cell Death 1 Receptor
authors with profiles
Abdulrafeh Naqash